| Lu D, Huang J, Basu A. Protein kinase Cepsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death. J Biol Chem. 2006 Aug 11;281(32):22799-807.
|
| |
| Mohanty S, Huang J, Basu. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin 1. Clin Cancer Res. 2005 Sep 15;11(18):6730-7.
|
| |
| Persaud SD, Hoang V, Huang J, Basu A. Involvement of proteolytic activation of PKCdelta in cisplatin-induced apoptosis in human small cell lung cancer H69 cells. Int J Oncol. 2005 Jul;27(1):149-54.
|
| |
| Lu D, Huang J, Basu A. Deregulation of PKB influences antiapoptotic signaling by PKC in breast cancer cells. Int J Oncol. 2004 Sep;25(3):671-6.
|
| |
| Huang J, Mohanty S, Basu A. Cisplatin resistance is associated with deregulation in protein kinase C-delta. Biochem Biophys Res Commun. 2004 Apr 16;316(4):1002-8.
|
| |
| Kumar Biswas S, Huang J, Persaud S, Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther. 2004 Mar;3(3):327-34.
|
| |
| Johnson CL, Lu D, Huang J, Basu A. Regulation of p53 stabilization by DNA damage and protein kinase C. Mol Cancer Ther. 2002 Aug;1(10):861-7.
|
| |
| Basu A, Miura A. Differential regulation of extrinsic and intrinsic cell death pathways by protein kinase C. Int J Mol Med. 2002 Nov;10(5):541-5
|
| |
| Basu A, Lu D, Sun B, Moor AN, Akkaraju GR, Huang J. Proteolytic activation of protein kinase C-epsilon by caspase-mediated processing and transduction of antiapoptotic signals. J Biol Chem. 2002 Nov 1;277(44):41850-6.
|
| |
| Mathew SO, Kumaresan PR, Lee JK, Huynh VT, Mathew PA. Mutational analysis of the human 2B4 (CD244)/CD48 interaction: Lys68 and Glu70 in the V domain of 2B4 are critical for CD48 binding and functional activation of NK cells. J Immunol. 2005 Jul 15;175(2):1005-13
|
| |
| Vaidya SV, Stepp SE, McNerney ME, Lee JK, Bennett M, Lee KM, Stewart CL, Kumar V, Mathew PA. Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells. J Immunol. 2005 Jan 15;174(2):800-7.
|
| |
| Lee JK, Boles KS, Mathew PA. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur J Immunol. 2004 Oct;34(10):2791-9.
|
| |
| 4 Lee KM, McNerney ME, Stepp SE, Mathew PA, Schatzle JD, Bennett M, Kumar V. 2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells. J Exp Med. 2004 May 3;199(9):1245-54.
|
| |
| Mathew PA, Chuang SS, Vaidya SV, Kumaresan PR, Boles KS, Pham HT. The LLT1 receptor induces IFN-gamma production by human natural killer cells. Mol Immunol. 2004 Mar;40(16):1157-63
|
| |
| Mathew PA, Chuang SS, Vaidya SV, Kumaresan PR, Boles KS, Pham HT. The LLT1 receptor induces IFN-gamma production by human natural killer cells. Mol Immunol. 2004 Mar;40(16):1157-63. |
| |
| Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002 Sep;39(1-2):1-8.
|
| |
| Chuang SS, Kim MH, Johnson LA, Albertsson P, Kitson RP, Nannmark U, Goldfarb RH, Mathew PA. 2B4 stimulation of YT cells induces natural killer cell cytolytic function and invasiveness.
Immunology. 2000 Jul;100(3):378-83.
|
| |
| Chuang SS, Lee Y, Stepp SE, Kumaresan PR, Mathew PA.Molecular cloning and characterization of the promoter region of murine natural killer cell receptor 2B4.Biochim Biophys Acta. 1999 Oct 28;1447(2-3):244-50.
|
| |
| Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48. J Exp Med. 1998 Dec 7;188(11):2083-90.
|
| |
| Jones HP, Tabor L, Sun X, Woolard MD, Simecka JW. Depletion of CD8+ T cells exacerbates CD4+ Th cell-associated inflammatory lesions during murine mycoplasma respiratory disease. J Immunol. 2002 Apr 1;168(7):3493-501.
|
